139194-79-9

Basic information

• Product Name: 3-Bromo-5-nitrobenzyl alcohol
• Synonyms: 3-Bromo-5-nitrobenzyl alcohol;(3-Bromo-5-nitrophenyl)methanol, 3-Bromo-5-(hydroxymethyl)nitrobenzene;(3-bromo-5-nitrophenyl)methanol;3-Bromo-5-nitrobenzylalcohol97%
• CAS NO: 139194-79-9
• Molecular Formula: C₇H₆BrNO₃
• Molecular Weight: 232.03
• Mol File: 139194-79-9.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-Bromo-5-nitrobenzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-nitrobenzyl alcohol(139194-79-9)
• EPA Substance Registry System: 3-Bromo-5-nitrobenzyl alcohol(139194-79-9)

Safety Data

• Hazardous Substances Data: 139194-79-9(Hazardous Substances Data)

Usage

Description

3-Bromo-5-nitrobenzyl alcohol is a chemical compound characterized by the molecular formula C7H6BrNO3. It is a white to off-white crystalline solid that serves as a versatile building block and reagent in the realm of organic synthesis. 3-Bromo-5-nitrobenzyl alcohol features a benzene ring with a bromine atom and a nitro group, complemented by an alcohol functional group, making it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and various organic materials. However, it is also recognized for its potential mutagenic and carcinogenic properties, necessitating careful handling and usage in both laboratory and industrial environments.

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-nitrobenzyl alcohol is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of drug molecules, contributing to the development of new medications and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-nitrobenzyl alcohol is employed as a precursor in the production of pesticides and other agrochemicals. Its reactivity and functional groups enable the synthesis of effective compounds designed to protect crops and enhance agricultural productivity.
Used in Organic Material Synthesis:
3-Bromo-5-nitrobenzyl alcohol is used as a versatile intermediate for the synthesis of organic materials, including dyes, polymers, and other specialty chemicals. Its structural features facilitate the development of innovative materials with unique properties and applications.
Used in Research and Development:
3-Bromo-5-nitrobenzyl alcohol is also employed in research and development settings, where its reactivity and structural attributes are harnessed to explore new chemical reactions and syntheses. This contributes to the advancement of organic chemistry and the discovery of novel compounds with potential applications across various industries.

Upstream product

• 111532-78-6 borane dimethyl sulfide complex 
• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 6307-87-5 methyl 3-bromo-5-nitrobenzoate 
• 121-92-6 3-nitrobenzoic acid 

Downstream Products

• 1273594-29-8 3-amino-5-bromobenzyl acetate 
• 1273594-30-1 3-amino-5-bromobenzyl benzoate 
• 1273594-22-1 1-bromo-3-[(methoxymethoxy)methyl]-5-aminobenzene 
• 1273594-23-2 1-bromo-3-[(methoxymethoxy)-methyl]-5-nitrosobenzene 
• 1273594-24-3 3-[(methoxymethoxy)methyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
• 1273594-21-0 1-bromo-3-[(methoxymethoxy)methyl]-5-nitrobenzene 
• 1251863-49-6 C₈H₈BrNO₃ 
• 1251863-50-9 C₈H₁₀BrNO 

Relevant articles and documents

A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low density lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small molecule inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavourable for binding by small organic molecules. Despite its challenging nature, we report herein the discovery of compound 3f as a small molecule inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chemistry, 3f emerged as a lead-like molecule by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered subcutaneously in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small molecule inhibitor against PCSK9 is therapeutically viable.

Pyrimidine compounds and pharmaceutical composition for preventing or treating cancers comprising the same

The present invention relates to a pyrimidine compound having excellent FLT3 inhibitory activity, and a pharmaceutical composition for preventing or treating a cancer, including the same. The pyrimidine compound is represented by chemical formula 14, wherein the pyrimidine compound is selected from a stereoisomer, a tautomer, a solvate, and a pharmaceutically acceptable salt thereof. In the chemical formula 14, E^a is hydrogen, hydroxy or C_(1-4) alkoxy, and E^b is hydrogen, halogen, C_(1-4) alkyl or C_(1-4) fluoroalkyl.COPYRIGHT KIPO 2019

Switchable 3D networks by light controlled π-stacking of azobenzene macrocycles

Azobenzene macrocycles were designed for switchable π-stacking interaction. After efficient preparation and characterization of azobenzene macrocycles containing electron rich as well as electron poor elements a dimeric analogue was synthesized, which formed reversibly 3D-networks. Gel formation was observed with aromatic solvents representing the first example of this type based on switchable azobenzene macrocycles. The Royal Society of Chemistry.